FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 12:46:37 04/06/2024 BST | ||
| 8.64 EUR | -0.80% |
|
| Current month | -5.12% | ||
| 1 month | -27.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/06/24 | 8.64 | -0.80% |
| 03/06/24 | 8.71 | -5.12% |
| 31/05/24 | 9.18 | -6.80% |
| 30/05/24 | 9.85 | +0.72% |
| 29/05/24 | 9.78 | +2.30% |
Real-time BOERSE MUENCHEN
Last update June 04, 2024 at 12:46 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LD |
| ISIN | DE000HD33LD6 |
| Date issued | 27/02/2024 |
| Strike | 705.3 $ |
| Maturity | Unlimited |
| Parity | 25.82 : 1 |
| Emission price | 10.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.8 € |
|---|---|
| Lowest since issue | 8.63 € |
| Spread | 0.02 € |
| Spread % | 0.23% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Certificates
- Certificat
